CVI Holdings’s Karyopharm Therapeutics KPTI Stock Holding History

CVI Holdings’s Portfolio KPTI Stock Details KPTI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-83,494	Closed	-$4.26M	–	429
2022 Q4	$4.26M	Buy	+83,494	New	+$5.79M	0.54%	61

Other funds holding KPTI

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

APM

Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

PAI

Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return

RCMNY

Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return

Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

CVI Holdings's KPTI Position: Q1 2023 in Review

CVI Holdings sold out of Karyopharm Therapeutics (KPTI) in Q1 2023, closing a stake of 83,494 shares — an estimated $4.26M sold.

CVI Holdings first reported a position in KPTI in Q4 2022 and held it in 1 quarter. The position peaked at $4.26M in Q4 2022. 129 funds tracked by Wall St. Rank hold KPTI as of Q1 2023.

CVI Holdings reported no remaining Karyopharm Therapeutics position as of Q1 2023 after selling out during the quarter.
CVI Holdings sold 83,494 Karyopharm Therapeutics shares in Q1 2023, an estimated $4.26M.
CVI Holdings first reported a position in Karyopharm Therapeutics in Q4 2022 and held it in 1 quarter.
CVI Holdings's Karyopharm Therapeutics position peaked at $4.26M in Q4 2022.
129 funds tracked by Wall St. Rank held Karyopharm Therapeutics as of Q1 2023.

Based on CVI Holdings's 13F filing for Q1 2023, filed 16 May 2023.